A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie (prior sponsor, Abbott)
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject must be ≥ 18 years of age
All subjects must have newly diagnosed, histologically proven adenocarcinoma of the rectum
All subjects must have an abdominal/pelvis computed tomography (CT ) scan or magnetic resonance imaging (MRI) confirming no evidence of distant metastases
Distal border of tumor \< 12 cm from anal verge
Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 to 2
No prior treatment for LARC however prior treatments for other cancers are acceptable as long as they are considered curative
You may not be if
Subject is an unsuitable candidate for TME surgery
Subject has received anticancer therapy
Subject has received prior radiation therapy
Subject has had major surgery within 28 days prior to the first dose of study drug
History of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption
Clareo Health | A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
